LENSAR (LNSR) vs MaxCyte (MXCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
MaxCyte (MXCT) has outperformed LENSAR (LNSR) over the past year, losing 37.7% versus a loss of 46.9%. Over five years, LNSR leads with a -15.3% price change compared with -90.8% for MXCT. MaxCyte is the larger company by market cap ($104.2 million vs $78.3 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LNSR | MXCT |
|---|---|---|
| Share price | $6.37 | $1.01 |
| Market cap | $78.26M | $104.24M |
| 1-day change | -1.24% | -0.98% |
| YTD return | -45.23% | -34.84% |
| 1-year return | -46.87% | -37.65% |
| 5-year return | -15.29% | -90.84% |
| P/E ratio (TTM) | 35.39 | — |
| EPS (TTM) | $0.18 | $-0.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.94 | $1.87 |
| 52-week low | $4.95 | $0.643 |
| Distance from 52-week high | -50.77% | -45.84% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +77.86% | +306.93% |
| Average volume | 103.43K | 656.97K |
| Shares outstanding | 12.29M | 103.21M |
| Employees | 150 | 91 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About LENSAR
LNSR stock →LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision.
Health Care · Medical/Dental Instruments · 150 employees
About MaxCyte
MXCT stock →MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 91 employees
LNSR vs MXCT FAQ
Which is bigger, LENSAR or MaxCyte?
MaxCyte (MXCT) is larger, with a market capitalization of $104.24M compared with $78.26M for LENSAR (LNSR).
Which stock has performed better over the past year, LNSR or MXCT?
MXCT returned -37.65% over the past 12 months, compared with -46.87% for LNSR (price return, excluding dividends). Past performance does not predict future results.
Are LENSAR and MaxCyte in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for LENSAR and Biotechnology: Commercial Physical & Biological Resarch for MaxCyte.